The stock of Novocure Ltd (NASDAQ:NVCR) is a huge mover today! About 135,692 shares traded hands. Novocure Ltd (NASDAQ:NVCR) has declined 43.00% since March 2, 2016 and is downtrending. It has underperformed by 51.26% the S&P500.
The move comes after 7 months positive chart setup for the $727.69 million company. It was reported on Oct, 5 by Barchart.com. We have $10.90 PT which if reached, will make NASDAQ:NVCR worth $174.65 million more.
Analysts await Novocure Ltd (NASDAQ:NVCR) to report earnings on October, 24. They expect $-0.40 EPS, up 80.86% or $1.69 from last year’s $-2.09 per share. After $-0.48 actual EPS reported by Novocure Ltd for the previous quarter, Wall Street now forecasts -16.67% EPS growth.
Novocure Ltd (NASDAQ:NVCR) Ratings Coverage
Out of 5 analysts covering NovoCure (NASDAQ:NVCR), 3 rate it a “Buy”, 1 “Sell”, while 1 “Hold”. This means 60% are positive. NovoCure has been the topic of 6 analyst reports since October 27, 2015 according to StockzIntelligence Inc. The company was initiated on Wednesday, December 2 by Deutsche Bank. The company was initiated on Tuesday, October 27 by Wedbush. On Tuesday, October 27 the stock rating was initiated by JMP Securities with “Market Outperform”. JP Morgan initiated Novocure Ltd (NASDAQ:NVCR) on Tuesday, October 27 with “Overweight” rating. Wedbush maintained the stock with “Outperform” rating in Friday, July 29 report. The stock has “Underweight” rating given by Barclays Capital on Tuesday, January 19.
According to Zacks Investment Research, “NovoCure Limited is an oncology company. The Company is engaged in developing a therapy called Tumor Treating Fields for the treatment of solid tumor cancers. It operates primarily in the United States, Germany, Switzerland and Japan. NovoCure Limited is based in Saint Helier, Channel Islands.”
More important recent Novocure Ltd (NASDAQ:NVCR) news were published by: Marketwatch.com which released: “Novocure Ltd. NASDAQ: NVCR” on September 21, 2015, also Fool.com published article titled: “Why Novocure Ltd Is Plunging Today”, Quotes.Wsj.com published: “Novocure Ltd. NVCR (US: Nasdaq)” on September 02, 2015. More interesting news about Novocure Ltd (NASDAQ:NVCR) was released by: Marketwatch.com and their article: “NovoCure falls below reduced IPO price in market debut” with publication date: October 02, 2015.
NVCR Company Profile
NovoCure Limited, incorporated on February 11, 2000, is a commercial-stage oncology company. The Firm is engaged in developing a therapy called TTFields for the treatment of solid tumor cancers. TTFields is a low-toxicity anti-mitotic treatment that uses low-intensity, intermediate frequency, alternating electric fields to exert physical forces on molecules inside cancer cells, disrupting the basic machinery for normal cell division, leading to cancer cell death. A TTFields delivery system includes a portable electric field generator, transducer arrays, rechargeable batteries and accessories. The electric fields are delivered through the non-invasive, insulated transducer arrays that are placed directly on the skin in the region surrounding the tumor. The therapy is designed to be delivered throughout the day and night.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.